https://scholars.lib.ntu.edu.tw/handle/123456789/568290
標題: | Elimination of hepatitis B in highly endemic settings: Lessons learned in Taiwan and challenges ahead | 作者: | CHUN-JEN LIU PEI-JER CHEN |
公開日期: | 2020 | 出版社: | MDPI AG | 卷: | 12 | 期: | 8 | 起(迄)頁: | 815 | 來源出版物: | Viruses | 摘要: | Hepatitis B virus (HBV) infection and its related liver diseases are important health problems worldwide, particularly in the Asia-Pacific region. For the past 4-5 decades, Taiwan's government and scientists have cooperated together to control this virus infection and its related liver diseases. These efforts and achievements have made progress toward the elimination of HBV. Taiwan's government initiated the Viral Hepatitis Control Program (VHCP) in the1970s, and then launched the national vaccination program in 1984. This universal vaccination program effectively decreased the rate of hepatitis B carriage and the development of hepatocellular carcinoma (HCC) in the younger generation. Since 2003, approved anti-HBV treatments were reimbursed nationwide. This reimbursement program resulted in a higher uptake of anti-HBV treatments, which contributed to a decrease in liver-related disease progression and subsequently reduced attributable mortality in Taiwan. This experience can be shared by countries in other parts of the world regarding the control of chronic viral hepatitis B. ? 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088906405&doi=10.3390%2fv12080815&partnerID=40&md5=6384675a92f7dad5f825110f78bbdcb9 https://scholars.lib.ntu.edu.tw/handle/123456789/568290 |
ISSN: | 1999-4915 | DOI: | 10.3390/v12080815 | SDG/關鍵字: | hepatitis B surface antigen; hepatitis B(e) antigen; hepatitis vaccine; active immunization; antiretroviral therapy; chemoprophylaxis; chronic hepatitis B; chronic kidney failure; end stage liver disease; health care cost; health insurance; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; highly active antiretroviral therapy; immunization; immunosuppressive treatment; liver cell carcinoma; liver cirrhosis; liver disease; liver fibrosis; mortality; mother to child transmission; Review; sexual transmission; vaccination; virus load; chronic hepatitis B; disease eradication; female; human; infant; liver tumor; male; prevention and control; preventive health service; Taiwan; vertical transmission; virology; Carcinoma, Hepatocellular; Disease Eradication; Female; Hepatitis B, Chronic; Humans; Immunization Programs; Infant; Infectious Disease Transmission, Vertical; Liver Neoplasms; Male; Taiwan; Vaccination; Viral Hepatitis Vaccines |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。